Insmed's lung infection drug fares no better than rival, shares fall

[riky]

Insmed's lung infection drug fares no better than rival, shares fall

(Reuters) - Insmed Inc's experimental lung infection drug fared no better than a competing drug developed by Novartis AG in a lung function test, sending shares in the company down 27 percent in pre-market trading. Insmed's drug, Arikace, was being tested as a treatment for a bacterial lung infection that often affects cystic fibrosis patients. Insmed said in a statement that the trial met its main goal of showing that Arikace was not inferior to the competing drug. ...

Source: You are not allowed to view links. Register or Login